Expanded Access Protocol (EAP) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming For Commercial Release

Grants and Contracts Details

StatusActive
Effective start/end date4/6/213/15/25

Funding

  • Celgene: $43,831.00